- Home
- EMCG vs RPID Comparison
EMCG vs RPID Comparison
Compare EMCG & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMCG
- RPID
- Stock Information
- Founded
- EMCG 2021
- RPID 2006
- Country
- EMCG United States
- RPID United States
- Employees
- EMCG N/A
- RPID N/A
- Industry
- EMCG
- RPID Medical Specialities
- Sector
- EMCG
- RPID Health Care
- Exchange
- EMCG NYSE
- RPID Nasdaq
- Market Cap
- EMCG 52.4M
- RPID 43.5M
- IPO Year
- EMCG 2022
- RPID 2021
- Fundamental
- Price
- EMCG $11.70
- RPID $1.23
- Analyst Decision
- EMCG
- RPID
- Analyst Count
- EMCG 0
- RPID 0
- Target Price
- EMCG N/A
- RPID N/A
- AVG Volume (30 Days)
- EMCG 2.6K
- RPID 144.4K
- Earning Date
- EMCG 01-01-0001
- RPID 02-28-2025
- Dividend Yield
- EMCG N/A
- RPID N/A
- EPS Growth
- EMCG N/A
- RPID N/A
- EPS
- EMCG 0.23
- RPID N/A
- Revenue
- EMCG N/A
- RPID $26,170,000.00
- Revenue This Year
- EMCG N/A
- RPID $24.34
- Revenue Next Year
- EMCG N/A
- RPID $19.49
- P/E Ratio
- EMCG $50.08
- RPID N/A
- Revenue Growth
- EMCG N/A
- RPID 27.31
- 52 Week Low
- EMCG $11.70
- RPID $0.58
- 52 Week High
- EMCG $13.39
- RPID $1.45
- Technical
- Relative Strength Index (RSI)
- EMCG 65.37
- RPID 65.59
- Support Level
- EMCG $11.63
- RPID $1.00
- Resistance Level
- EMCG $11.74
- RPID $1.37
- Average True Range (ATR)
- EMCG 0.00
- RPID 0.12
- MACD
- EMCG 0.00
- RPID 0.03
- Stochastic Oscillator
- EMCG 55.56
- RPID 62.07
About EMCG EMBRACE CHANGE ACQUISITION CORP
Embrace Change Acquisition Corp is a blank check company. It is formed for the purpose of entering into a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.